URL has been copied to clipboard.

Early Intervention for GA and Use of FDA-Approved Therapies Masterclass

Early Intervention for GA and Use of FDA-Approved Therapies Masterclass

The Fundingsland Group, in collaboration with the John A. Moran Eye Center at the University of Utah, is proud to announce the inaugural GA Masterclass. This premier educational initiative is designed for early-career retina specialists and fellows aiming to lead the future of geographic atrophy (GA) care secondary to age-related macular degeneration (AMD).

Why This Masterclass Matters

Geographic atrophy is a growing challenge in retinal disease management, with significant implications for patient vision and quality of life. FDA-approved anti-complement therapies are reshaping treatment pathways, but effective adoption requires both advanced expertise and practical strategies for clinical implementation.

The GA Masterclass aims to:

  • Strengthen skills in diagnosis, treatment, and management of GA

  • Provide best practices for integrating FDA-approved therapies into practice

  • Improve patient education and compliance

  • Address management, workflow, and reimbursement strategies

Program Highlights

The 30-hour GA Masterclass will accommodate 30 learners participating in the following exclusive activities led by some of the top retinal surgeons in the United States:

  • Mentor-guided didactic modules

  • Interactive live webinars covering the latest literature and clinical questions

  • Knowledge exchange with mentors and peers

  • In-person case review grand rounds at the Moran Eye Center (March 20–21, 2026)

  • Wet labs, workshops, and professional development activities (March 20–21, 2026)

  • Access to ongoing webinars for 12 months post-program

By combining structured learning, mentorship, and hands-on training, the GA Masterclass aims to elevate practice patterns, improve clinical outcomes, and expand access to treatment for patients with GA due to AMD.

Apply Now

Applications are now open. The deadline to apply is December 15, 2025.

👉 Don’t miss this exclusive opportunity to join a cohort of 30 learners at the forefront of retinal disease management.